NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $78.39 +0.19 (+0.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$78.19 -0.20 (-0.26%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Incyte Stock (NASDAQ:INCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Incyte alerts:Sign Up Key Stats Today's Range$77.69▼$79.0050-Day Range$65.31▼$78.3952-Week Range$53.56▼$83.95Volume1.16 million shsAverage Volume1.69 million shsMarket Capitalization$15.31 billionP/E Ratio17.82Dividend YieldN/APrice Target$81.20Consensus RatingHold Company Overview Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. Read More Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 94% of companies evaluated by MarketBeat, and ranked 59th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 7 buy ratings, 10 hold ratings, and 1 sell rating.Amount of Analyst CoverageIncyte has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth34.57% Earnings GrowthEarnings for Incyte are expected to grow by 34.57% in the coming year, from $4.86 to $6.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 17.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 17.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.95.Price to Earnings Growth RatioIncyte has a PEG Ratio of 0.62. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.73% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 2.33%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Sustainability and ESG2.8 / 5Environmental Score-2.69 Percentage of Shares Shorted3.73% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 2.33%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.78 News SentimentIncyte has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Incyte this week, compared to 19 articles on an average week.Search InterestOnly 8 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,836,196.00 in company stock.Percentage Held by Insiders17.80% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesIncyte Corporation (NASDAQ:INCY) EVP Sells $251,785.64 in StockJuly 24, 2025 | insidertrades.comIncyte Corporation (NASDAQ:INCY) EVP Sells $82,225.22 in StockJuly 17, 2025 | insidertrades.comA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.August 9 at 2:00 AM | American Alternative (Ad)Incyte (NASDAQ:INCY) Upgraded at Wells Fargo & CompanyAugust 9 at 2:31 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Incyte (INCY) and Y-Mabs Therapeutics (YMAB)August 8 at 6:17 PM | theglobeandmail.comImpressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)August 7 at 8:56 PM | finance.yahoo.comIncyte Corporation (INCY) Announces CFO DepartureAugust 7 at 10:34 AM | gurufocus.comIncyte CFO Christiana Stamoulis to Step DownAugust 7 at 9:51 AM | tipranks.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $69.07 at the beginning of the year. Since then, INCY stock has increased by 13.5% and is now trading at $78.39. How were Incyte's earnings last quarter? Incyte Corporation (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.15. The business's revenue was up 19.5% compared to the same quarter last year. Read the conference call transcript. Who are Incyte's major shareholders? Top institutional shareholders of Incyte include Geode Capital Management LLC (2.23%), Acadian Asset Management LLC (1.27%), Robeco Institutional Asset Management B.V. (1.23%) and Bank of New York Mellon Corp (0.64%). Insiders that own company stock include Steven H Stein, Maria E Pasquale, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings4/29/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,617Year Founded1991Price Target and Rating Average Price Target for Incyte$81.20 High Price Target$107.00 Low Price Target$60.00 Potential Upside/Downside+3.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$4.40 Trailing P/E Ratio17.82 Forward P/E Ratio16.13 P/E Growth0.62Net Income$32.62 million Net Margins18.99% Pretax Margin27.53% Return on Equity21.99% Return on Assets14.43% Debt Debt-to-Equity Ratio0.01 Current Ratio2.85 Quick Ratio2.78 Sales & Book Value Annual Sales$4.24 billion Price / Sales3.61 Cash Flow$0.55 per share Price / Cash Flow141.26 Book Value$21.36 per share Price / Book3.67Miscellaneous Outstanding Shares195,280,000Free Float160,517,000Market Cap$15.31 billion OptionableOptionable Beta0.71 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:INCY) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.